Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CL002NK CAR-NK cells in advanced hepatocellular carcinoma after first-line treatment failure
ChiCTR2500100889Phase 2Not yet recruiting
- Sponsor
- Third Affiliated Hospital of Naval Medical University
- Start
- Apr 2025
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of CL002NK in hepatocellular carcinoma (HCC) (2 arms), sponsored by Third Affiliated Hospital of Naval Medical University. Primary endpoints: Dose-limiting toxicity and Adverse events. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
CL002NK
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2500100889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500100889.